An analysis of clinical and pathological features of 148 cases of drug-induced liver injury

Abstract

Abstract: Objective To analyze the clinical characteristics of drug-induced liver injury (DILI) patients with different clinical classifications and to compare the relationship between clinical and pathological classifications.Methods This study retrospectively screened DILI patients who underwent liver punctures with RUCAM>6 points in Nanjing Second Hospital from January 2018 to December 2022. Data of age, gender, medication history, disease course, liver function indexes and pathological results were collected.Results A total of 200 patients met the inclusion criteria, and 148 patients were included in the analysis after exclusion criteria. The median age of the 148 patients was 49.5 years. The male to female ratio was 1∶1.96. The drugs suspected of liver damage were divided into three categories, i.e., traditional Chinese medicine, western medicine, and mixed Chinese and western medicine, accounting for 45.3%, 43.9% and 10.8% of the cases, respectively. The main clinical classifications were hepatocellular injury (40.5%); The analysis of pathological classifications in DILI patients with different severities showed that inflammatory necrosis type was the main type among mild and moderate cases, and cholestatic type was mainly distributed in severe and acute liver failure cases. The correlation analysis between the clinical and pathological classifications of the DILI patients showed that the Cramer’s V coefficient value was 0.264 (P<0.05).Conclusion There is a certain correlation between pathological and clinical classifications of DILI patients but the relationship is moderate.

Key words: Drug induced liver injury, Clinical classification, Pathological classification, Correlation

WANG Shuang-shuang, XIONG Qing-fang, HU Yi-fan, CHEN Miao-yang, YANG Yong-feng. An analysis of clinical and pathological features of 148 cases of drug-induced liver injury[J]. Chinese Hepatolgy, 2023, 28(11): 1280-1284.

References

[1] Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013,144(7):1419-1425.
[2] Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives[J]. Gastroenterology,2014,146(4):914-928.
[3] Miguel A, Azevedo LF, Pereira AC, et al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis[J]. Pharmacoepidemiol Drug Saf,2012,21(11):1139-1154.
[4] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志,2015,31(11) :1752-1769.
[5] 杨永峰. 药物性肝损伤病理学的特征及鉴别诊断[J]. 临床肝胆病杂志,2021,37(11):2530-2534.
[6] European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019,70(6):1222-1261.
[7] Cho J, Kim L, Li ZX, et al. Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/cmice: suggested roles for Tregs, estrogen, and IL-6[J]. PLoS One,2013,8(4):e61186.
[8] Wang CY, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study[J]. Hepatology, 2022,75(6):1373-1385.
[9] Rathi C, Pipaliya N, Patel R, et al. Drug induced liver Injury at a tertiary hospital in India: etiology, clinical features and predictors of mortality[J]. Ann Hepatol,2017,16(3):442-450.
[10] Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury[J]. Gastroenterology, 2010,138(7):2246-2259.
[11] Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances[J]. Expert Opin Drug Metab Toxicol,2011,7(7):875-890.
[12] Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury[J]. LiverInt,2019,39(1):31-41.
[13] Shen T, Liu YX, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China[J]. Gastroenterology,2019,156(8):2230-2241.
[14] 赵娇, 肖丽. 170例药物性肝损伤患者临床特征分析[J]. 肝脏,2022,27 (6):683-687.
[15] 范颖, 赵红, 谢雯. 中国首部《药物性肝损伤防治指南》解读[J]. 中华全科医师杂志,2016,15(6):416-420.
[16] 朱春雾, 王海南, 袁继丽, 等. 445例药物性肝损伤的临床分析[J]. 临床肝胆病杂志, 2018,34(2):354-358.
[17] Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug- induced liver injury: the DILIN prospective study[J]. Gastroenterology,2015,148(7) :1340-1352.
[18] Kaplowitz N. Idiosyncratic drug hepatotoxicity[J]. Nat Rev Drug Discov,2005,4(6):489-499.
[19] Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug- induced liver injury[J]. Gastroenterology,2014,147(1):109-118.
[20] Kleiner DE. The histopathological evaluation of drug-induced liver injury [J]. Histopathology. 2017,70(1):81-93.
[21] Ashby K, Zhuang W, González-Jimenez A, et al. Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI[J]. J Hepatol, 2021,75(2):333-341.
[22] 郭立杰,王超,伍彦辉,等. 药物性肝损伤不同时间临床分型与病理损伤分型关联性分析[J]. 临床误诊误治, 2020,33(4):40-45.
[23] 叶立红, 王翀奎, 邵晨, 等. 胆管细胞损伤型药物性肝损伤病理与临床生化特征分析[J]. 临床肝胆病杂志, 2020,36(5):1059-1054.